Discovery and development of COVID-19 vaccine from laboratory to clinic.

The world has recently experienced one of the biggest and most severe public health disasters with severe acute respiratory syndrome coronavirus (SARS-CoV-2). SARS-CoV-2 is responsible for the coronavirus disease of 2019 (COVID-19) which is one of the most widespread and powerful infections affecting human lungs. Current figures show that the epidemic had reached 216 nations, where it had killed about 6,438,926 individuals and infected 590,405,710. WHO proclaimed the outbreak of the Ebola virus disease (EVD), in 2014 that killed hundreds of people in West Africa. The development of vaccines for SARS-CoV-2 becomes more difficult due to the viral mutation in its non-structural proteins (NSPs) especially NSP2 and NSP3, S protein, and RNA-dependent RNA polymerase (RdRp). Continuous monitoring of SARS-CoV-2, dynamics of the genomic sequence, and spike protein mutations are very important for the successful development of vaccines with good efficacy. Hence, the vaccine development for SARS-CoV-2 faces specific challenges starting from viral mutation. The requirement of long-term immunity development, safety, efficacy, stability, vaccine allocation, distribution, and finally, its cost is discussed in detail. Currently, 169 vaccines are in the clinical development stage, while 198 vaccines are in the preclinical development stage. The majority of these vaccines belong to the Ps-Protein subunit type which has 54, and the minor BacAg-SPV (Bacterial antigen-spore expression vector) type, at least 1 vaccination. The use of computational methods and models for vaccine development has revolutionized the traditional methods of vaccine development. Further, this updated review highlights the upcoming vaccine development strategies in response to the current pandemic and post-pandemic era, in the field of vaccine development.

Adsorption isotherm, kinetics and response surface methodology optimization of cadmium (Cd) removal from aqueous solution by chitosan biopolymers from cephalopod waste.

The present investigation was aimed to explore the cadmium removal efficiency, mechanism and characterization of Chitosan biopolymers from cephalopods waste. The extracted chitosan has showed good yield of 32% and with high minerals, ash and moisture content. In the Fourier-transform infrared spectroscopy (FT-IR) analysis multiple active functional groups of Amine, Amine, Hydroxyl were found between 612 and 3424 cm-1 and the sugar signals such as N-acetyl glucosamine (GlcNAc) and H-1 [GlcN (H-1D), GlcNAc (H-1A)] were identified in Chitosan by 1H Nuclear Magnetic Resonance (NMR). The Crystalline, rough surface, micropores characters were observed in Chitosan surface by Scanning Electron Microscope (SEM) analysis and the pores played a key role in adsorption process. The Cd ions removal was performed by batch experiment and the results were revealed that the pH, temperature, time and dosage highly influenced the process and the optimum condition was discovered through RSM for pH 7, temperature 42.5 °C, time 220 min and dosage of sorbent 1 g/L respectively. The kinetics models of the Cd removal were carried out and the results revealed that the Pseudo-second order is more suitable and fit for removal than Pseudo-first order model. Chitosan surface characters and functional groups played a big role in adsorption process and Chitosan can be alternative eco-friendly, low cost and highly efficient sorbent for heavy metal removal in effluent treatment plants.